shares in zur rose group ag almost doubled in opening trade after the online pharmacist said it reached a deal to divest its operations in its home country switzerland to migros group as it looks to focus on its business in germany migros healthcare subsidiary medbase will acquire all zur roses switzerland operations for a price of around 360 million swiss francs 3942 million the transaction set to be completed in the second quarter this year will clear zur roses net debt and strengthen its capital structure the company said friday the divestment will allow zur rose to focus on its german business where it sees strong growth potential from the rollout of electronic prescriptions the focus lies on profitable growth zur rose said the acquisition fee will entail a first payment upon complement of the sale with an earnout of chf47 million payable based on reaching its 2023 earnings target zur rose said the companys financial guidance for 2022 remains unchanged while new targets for further ahead will be set out alongside fullyear results next month the company said zur rose said in january it expects an adjusted loss before interest taxes depreciation and amortization of chf70 millionchf75 million for 2022 and to reach ebitda breakeven in 2023